Pitazone

Quick links to important sections

Pitazone

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pitazone

Property Description
Active ingredient Pioglitazone Hydrochloride
Form Tablet
Pharmacological class Thiazolidinedione (Glitazone)
General purpose Improvement of insulin sensitivity
Origin Synthetic Compound

What is Pitazone and its Chemical Identity?

Pitazone is an oral, prescription-only medication whose active component is the synthetic compound Pioglitazone Hydrochloride (INN). It is supplied as a solid dose tablet, necessitating oral administration for systemic effect. This pharmaceutical product is a single-ingredient preparation, characterized by the precise chemical nature of the Pioglitazone thiazolidinedione derivative. As a product based on this INN, Pitazone serves the specific patient group managing chronic metabolic conditions that necessitate daily oral therapy.

Classification: The Thiazolidinedione (Glitazone) Pharmacological Class

Pitazone is formally recognized as an Antihyperglycemic Agent, belonging exclusively to the Thiazolidinedione (TZD) class of drugs, also known as Glitazones. This classification is clinically recognized for addressing a key metabolic issue: insulin resistance. Unlike other classes that manage glucose by modulating intestinal absorption or pancreatic function, the TZD class has a unique mechanism centered on enhancing cellular response to endogenous insulin.

General Purpose: Targeting Insulin Resistance

The core purpose of Pitazone is to act as an insulin sensitizer. This function is achieved through the targeted action of Pioglitazone as a Peroxisome Proliferator-Activated Receptor Gamma (PPAR Gamma) Agonist. By modulating this key intracellular receptor, the medicine helps tissues, particularly muscle and fat, utilize glucose more effectively. The general therapeutic goal of Pitazone is to improve glycemic control by correcting this underlying mechanism, offering a foundational element in a patient's long-term strategy for managing the condition.

What side effects are possible with Pitazone?

Possible Side Effects and Safety Information

The safety profile of Pitazone (Pioglitazone) is officially documented by government regulatory agencies and is characterized by a range of adverse reactions classified by their frequency of occurrence in clinical use.

Fluid retention, known as Edema, is the most frequently observed reaction, often classified as Very Common in regulatory summaries. Other Common adverse effects include Upper Respiratory Tract Infection, Headache, Myalgia (muscle pain), Pharyngitis, Sinusitis, and Weight Increased, the latter being recognized as a dose-related effect.

Serious and clinically significant safety concerns are highlighted in official labeling, primarily affecting the cardiac, oncologic, and hepatic systems. Congestive Heart Failure (CHF), including serious and fatal cases, is a major regulatory concern, and the medicine is strictly contraindicated in patients with established New York Heart Association (NYHA) Class III or IV heart failure. There is also a documented association between Pioglitazone use and an increased risk of Bladder Cancer, with the risk cited as potentially higher with increased duration of exposure.

Additionally, the label notes risks for specific populations. An increased incidence of non-vertebral Bone Fractures has been observed specifically in female patients. Treatment is contraindicated in individuals with active liver disease due to the potential for fatal or nonfatal Hepatic Failure. When used in combination with insulin or sulfonylureas, the risk of Hypoglycemia (low blood sugar) is increased.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding Pitazone (Pioglitazone Hydrochloride) overdose is based strictly on descriptions and instructions found in official government regulatory documents.

Documented Clinical Manifestations

The primary expected clinical presentation of an overdose event is hypoglycemia (low blood sugar), particularly if the medication is taken in excess or combined with other glucose-lowering agents, as stated in prescribing information. While one case involving a high acute dose (120 mg/day for seven days) was documented as resulting in no clinical symptoms, the risk of severe metabolic effects remains the primary concern.

Emergency Actions Mandated by Regulators

Official guidance requires immediate contact with medical professionals or emergency services in the event of suspected overdose. Immediate help is required if the person exhibits acute symptoms such as collapse, seizure, trouble breathing, or unresponsiveness.

  • Call emergency services (911) for any life-threatening symptoms.
  • Contact the poison control helpline for guidance in less severe cases.

Regulatory documents confirm that no specific antidote is available for Pioglitazone overdose. Therefore, management must be supportive, with treatment and observation guided by the patient’s specific clinical status and symptoms.

Therapeutic Uses of Pitazone

What Pitazone Treats: Main Uses and Benefits

Pitazone is commonly used to help manage conditions characterized by systemic imbalance and heightened physiological activity, such as Type 2 Diabetes. The medication is applied across therapeutic domains where additional symptomatic support is needed. It is considered relevant for easing symptoms related to physical discomfort and addressing symptom clusters that may become intense or disruptive. This intervention provides support that helps ease the overall symptom burden associated with the condition.


Key Therapeutic Focus

Pitazone is commonly used across conditions presenting with episodic or fluctuating manifestations and those associated with acute or disruptive episodes. It is often applied during phases when symptoms become more noticeable, offering supportive relief when symptoms interfere with daily functioning. It is commonly used across conditions presenting with systemic discomfort and those where functional stability becomes affected.

“This medication may contribute to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes.”

Quick Fact: Managing Symptom Clusters


Benefit in Symptom Stabilization

In clinical settings that involve acute or unstable symptom patterns, Pitazone may assist with supporting functional stability. It is relevant when short-term symptomatic assistance is needed and helps maintain a sense of stability when symptoms are more noticeable. It is considered relevant for managing symptoms that create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Pitazone — Official Regulatory Information

Pitazone (Pioglitazone) is indicated only for use in adult patients (aged 18 and over) with Type 2 Diabetes Mellitus. The eligibility profile is strictly defined by regulatory authorities to exclude specific populations based on pre-existing conditions and physiological status.


Eligibility Scope Status Defined by Regulators
Populations for whom use is allowed Adults (18+) with Type 2 Diabetes Mellitus
Populations for whom use is contraindicated Patients with established NYHA Class III or IV heart failure or a history of heart failure. Patients with active liver disease or elevated baseline liver enzymes (ALT > 2.5x ULN). Patients with current or history of bladder cancer. Patients with diabetic ketoacidosis or known hypersensitivity to the drug.
Age-related eligibility rules Not recommended for children and adolescents (under 18 years) as safety and efficacy have not been established. Geriatric use requires starting at the lowest available dose.
Physiological Status Limitations Should not be used during pregnancy or administered to breastfeeding women. Use is not recommended for patients with Type 1 Diabetes Mellitus or those with renal impairment on dialysis.

Connection to the overall eligibility profile The regulatory documents formally define who can and cannot use the medicine by establishing numerous absolute prohibitions (contraindications) tied to specific organ status, notably the heart, liver, and bladder. Use is further excluded or classified as not recommended for age groups outside of adults, as well as during pregnancy and lactation. This structure ensures adherence to official, established patient criteria.

What should I know about interactions with other medicines?

Pitazone Interactions with other medicines and products

The interaction profile of Pitazone (Pioglitazone) is defined by modifications to its metabolism and its combination with agents that affect fluid or glucose balance. No medicinal product combinations are formally classified as contraindicated based on drug-drug interaction risk in major regulatory labels. Restrictions imposed are based on managing altered exposure or additive physiological effects.

Type of Interaction Interacting Agents Official Regulatory Statement
Pharmacokinetic (CYP2C8 Inhibition) Strong CYP2C8 Inhibitors (e.g., Gemfibrozil) Co-administration increases Pitazone plasma concentration (AUC) approximately threefold, restricting the maximum dose of Pitazone to 15 mg daily.
Pharmacokinetic (CYP2C8 Induction) CYP2C8 Inducers (e.g., Rifampin, Topiramate) May decrease Pitazone plasma concentrations.
Pharmacodynamic (Glucose) Insulin and Insulin Secretagogues Increased risk of hypoglycemia, requiring dose adjustment (reduction) of the co-administered agent.
Pharmacodynamic (Fluid Retention) Insulin and NSAIDs/COX-2 Inhibitors Increased risk of fluid retention due to an additive effect.

Pitazone can be taken without regard to meals, as food does not significantly affect its overall absorption. Regarding population-specific interaction considerations, co-administration with Insulin requires caution in the elderly due to the increased potential for serious fluid retention, as documented in regulatory information. The interaction structure relies on constraints related to metabolic modifiers and additive clinical effects.

Mechanism of Action

Pitazone (Pioglitazone) works by acting as a synthetic ligand for nuclear receptors, primarily modifying gene transcription in metabolically active tissues, including adipose tissue, skeletal muscle, and the liver.

Peroxisome Proliferator-Activated Receptor (PPAR) Agonism

Pitazone binds to and activates PPAR-gamma (gamma) and PPAR-alpha (alpha) nuclear receptors. This crucial initial step initiates signaling sequences that lead to the downstream regulation of gene transcription, representing the key initiation step for the drug's action.

Transcriptional Modulation of Metabolic Pathways

Activation of these receptors modifies the expression of numerous genes controlling carbohydrate and lipid metabolism. This includes increasing the transcription of genes for glucose transporters (like GLUT4) and adipokines (like adiponectin), resulting in increased cellular sensitivity to insulin signaling.

Regulation of Systemic Metabolism

Through the modulation of processes driven by specific signaling patterns, Pitazone exerts key pathway effects on target tissues. This includes promoting glucose uptake and utilization in muscle and fat cells, while simultaneously decreasing the liver's production of glucose (gluconeogenesis). This results in systemic physiological changes that influence glucose homeostasis.

Dosage and Administration Information

Pitazone is an oral medicine that is administered as a solid dose tablet. The official instructions specify a once-daily dosing schedule that provides flexibility, as the medicine may be taken with or without food. Regardless of meal timing, the tablet should be swallowed whole with water.

The standard adult dosing regimen begins at 15 mg or 30 mg once daily. Doses can be adjusted in 15 mg increments, up to the maximum labeled daily dose of 45 mg. Regulatory guidelines mandate a lower starting dose for certain patient groups, such as older adults, who must initiate therapy at the lowest available dose. A specific dose restriction to a maximum of 15 mg daily is also required when Pitazone is used concurrently with strong CYP2C8 inhibitors.

The overall use protocol is defined by a necessary three to six-month review period, during which the prescriber should confirm the treatment's sustained appropriateness. Pitazone is not recommended for use in children and adolescents under 18.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pitazone

The evidence for Pitazone (Pioglitazone) is derived from official clinical trials, systematic reviews, and meta-analyses. This overview describes the structure of the research and the patterns observed in the studies, highlighting what has been explored and what remains an area of active study.


Evidence for Glycemic Control in Systemic Metabolic Imbalance

Research exploring the effects of Pitazone primarily takes the form of Randomized Controlled Trials (RCTs). These studies was evaluated in adults with Type 2 Diabetes, including those who were newly diagnosed and those whose blood sugar was not adequately managed by other therapies. The key outcomes monitored in these trials were changes in long-term average blood sugar, such as Glycosylated Hemoglobin (HbA1c), and technical indices used to assess the body's response to its own insulin.

Studies reported measurable shifts occurred in these glycemic biomarkers during the study period. However, the majority of the foundational research for this context involved follow-up durations up to one year, which means the studies provide limited information for long-term outcomes that are not fully characterized beyond those timeframes.

Research on Long-Term Outcomes and Systemic Risk Factors

For patients with established systemic risk factors, research includes large-scale, long-term RCTs (Cardiovascular Outcome Studies). These multi-year trials was studied for their potential influence on the occurrence of serious events, including non-fatal heart attack (MI), non-fatal stroke, and cardiovascular death. The populations studied were adults with Type 2 Diabetes who had a high cardiovascular risk profile due to existing macrovascular disease.

The large outcome trials report that data show patterns related to the rate of Major Adverse Cardiovascular Events (MACE) occurrence in the Pitazone group over the study period. Data show patterns related to all-cause mortality that were mixed when various long-term studies were analyzed together.


Understanding Evidence Gaps and Areas of Uncertainty

The research on Pitazone, while extensive in some areas, contains clear limitations that must be acknowledged. Comparative evidence is lacking in some areas, particularly concerning direct, head-to-head comparisons against some of the newer anti-diabetic medications. Furthermore, data for certain groups remain limited, and the long-term impact on functional health and quality of life is not fully established by existing studies.

Key Studies & References

  1. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
  2. NICE guideline [NG28] - Type 2 diabetes in adults: management

Frequently Asked Questions (FAQ)

Common questions about Pitazone (FAQ)


Q: Is Pitazone considered a first-line medication for diabetes management?

Official product information indicates that Pitazone can be used either by itself (monotherapy) or combined with other diabetes medicines, such as insulin or metformin. Regulatory documents do not universally specify it as the initial first-line treatment for all adults with Type 2 Diabetes.


Q: How long does it typically take to see the expected effects of Pitazone?

Pitazone is a drug that works by gradually modifying how the body responds to insulin, a complex process called gene modulation. Because of this mechanism, its full effect on lowering blood glucose is not immediate. Studies indicate it may take up to two to three months of consistent use to reach its maximal effect.


Q: Does the weight gain associated with Pitazone come from fluid retention or fat?

Official information confirms that an increase in body weight is a common side effect of Pitazone. This weight gain is reported to involve a combination of both fluid retention (edema) and an increase in subcutaneous fat tissue, based on pharmacodynamic studies.


Q: What kind of vision changes are people concerned about when taking Pitazone?

Postmarketing reports mention the new onset or worsening of a condition called diabetic macular edema (DME). This swelling at the back of the eye can result in blurred vision or a decrease in overall visual sharpness.


Q: Is Pitazone known to cause low blood sugar (hypoglycemia) on its own?

When Pitazone is used alone (monotherapy), the risk of low blood sugar, known as hypoglycemia, is reported as very low. However, official safety information states that the risk significantly increases when Pitazone is taken alongside other medicines that stimulate insulin, such as insulin itself or sulfonylureas.


Q: Can Pitazone be taken at the same time as cold and flu medications?

Many cold and flu medicines contain ingredients, such as decongestants or steroids, that are known to interfere with blood glucose control. If these are co-administered, the patient's existing regimen may necessitate close monitoring of blood glucose levels to account for possible effects on blood sugar.


Q: Are there foods or drinks that should be avoided because they interact with Pitazone?

According to official regulatory labeling, Pitazone can be taken with or without food. Food intake does not significantly change the amount of medicine the body absorbs. No specific food or drink avoidance is required due to direct interaction with the medicine itself.


Q: Is there a known interaction between Pitazone and alcohol consumption?

While there is not always a formal contraindication for Pitazone alone, alcohol use may potentially increase the risk of low blood sugar (hypoglycemia). This risk is particularly noted when Pitazone is used in combination with other anti-diabetic agents.


Q: Does Pitazone interact with oral contraceptive pills (birth control)?

Studies suggest that Pitazone may reduce the effectiveness of some types of combined oral contraceptives (birth control pills) by affecting how the body processes them. Due to this potential interaction, clinical follow-up regarding the effectiveness of the contraceptive may be necessitated.


Q: How does Pitazone interact with medicines used to treat high blood pressure?

Pitazone can cause fluid retention (edema), which may complicate conditions like high blood pressure (hypertension). Using Pitazone with other medications that also cause fluid retention may lead to an additive effect, increasing the overall fluid in the body.


Q: Is it true that Pitazone can cause ovulation in some premenopausal women?

Yes, official regulatory precautions note that this medicine may cause some premenopausal women who do not have regular monthly periods to ovulate. This change can increase the likelihood of becoming pregnant.


Q: What does the term 'macular edema' mean in the context of Pitazone side effects?

Macular edema is a medical term that refers to swelling of the macula, which is the center part of the retina at the back of the eye. This condition has been reported in post-marketing experience associated with Pitazone and can be a cause of decreased vision.


Q: What is the scientific basis for the requirement to monitor body weight while taking Pitazone?

Official prescribing information requires monitoring for rapid or unexplained weight gain because it may signal a serious safety concern. Specifically, it can be an early indicator of worsening heart failure or significant fluid retention (edema).


Q: Is Pitazone still being used in new clinical trials or studies?

Yes, even though Pitazone is an established medication, it continues to be the subject of ongoing or recently completed clinical trials. These studies, which are tracked in official regulatory databases, examine the drug for various effects and in different patient populations.


Q: What happens if Pitazone is taken alongside a steroid medication?

Corticosteroids, commonly known as steroids, are known to cause hyperglycemia and interfere with blood glucose control. Taking a steroid medication alongside Pitazone may interfere with blood sugar control. Due to this interference, this co-administration necessitates clinical oversight regarding glucose monitoring and potential dosage adjustments.


Q: What is the maximum duration of use for Pitazone that has been studied in clinical trials?

Regulatory documents rely on large-scale, long-term randomized controlled trials (RCTs) that have studied the effects of Pitazone over multiple years. These multi-year studies are essential for assessing cardiovascular outcomes and the overall long-term safety profile.


Q: Does Pitazone affect cholesterol or triglyceride levels in the blood?

Official clinical study data indicates that Pitazone does affect the body's lipids (fats). It is generally shown to increase levels of HDL (often called 'good cholesterol') and help reduce triglyceride levels. A modest increase in LDL cholesterol may also occur.

How should Pitazone be stored and disposed of?

How to Store and Dispose of Pitazone?

Storage Conditions

Pitazone tablets must be stored at Controlled Room Temperature, defined as 25 C (77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F). The medication must be kept in its original container with the lid tightly closed to protect it from moisture, humidity, and excessive heat. Do not freeze the tablets. For safety, Pitazone must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Pitazone should be disposed of according to official regulatory protocol. The preferred method is through a local drug take-back program. If a take-back option is unavailable, the tablets must be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed bag, and then discarded in the household trash. The original container's label should have all personal information removed before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pitazone found in:

A-Z Index: